Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
All city buildings in Chicago are now powered by renewable energy
BY THE OPTIMIST DAILY EDITORIAL TEAM Chicago entered 2024 with a landmark achievement: every one of its 411 municipal buildings, from City Hall to ...
Read MoreHow unique leopard calls could impact conservation
BY THE OPTIMIST DAILY EDITORIAL TEAM Leopards, renowned for their stealth and solitary nature, have always been challenging to study. However, groundbreaking research revealed that ...
Read MoreThese solar-powered barges can scoop up 50 tons of plastic from rivers each day
While removing the plastic waste that currently contaminates the ocean today will be crucial for protecting marine ecosystems, it is arguably more important that ...
Read MoreWashington’s first human compost company is open for business
Washington passed a law in 2019 allowing citizens to compost themselves after death for a more sustainable burial process. Fast forward a year later ...
Read More
